
Keros Therapeutics, Inc.: updates and filings
Price
$11.08
November 20, 2026Market cap $218M
What Ploutos Investor adds for Keros Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
June 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Other material eventsForm8-K
- Nov 5, 2026Regulation FD disclosureForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 29, 2026Regulation FD disclosureForm8-K
- Sep 28, 2026Regulation FD disclosureForm8-K
- Sep 16, 2026FilingFormEFFECT
- Sep 11, 2026FilingFormDEL AM
- Sep 10, 2026Shelf registration for future offeringsFormS-3
- Sep 8, 2026Other material eventsForm8-K
- Aug 3, 2026Regulation FD disclosureForm8-K
- Aug 3, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Results of operationsForm8-K
- Jul 30, 2026Regulation FD disclosureForm8-K
- Jul 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 22, 2026Officer or director changeForm8-K
- Jul 17, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 25, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jun 3, 2026Shareholder voteForm8-K
- Jun 1, 2026Regulation FD disclosureForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operationsForm8-K
- Apr 22, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 8-K | Other material events | Document |
| Nov 5, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 29, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 28, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 16, 2026 | EFFECT | Filing | Document |
| Sep 11, 2026 | DEL AM | Filing | Document |
| Sep 10, 2026 | S-3 | Shelf registration for future offerings | Document |
| Sep 8, 2026 | 8-K | Other material events | Document |
| Aug 3, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 3, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Results of operations | Document |
| Jul 30, 2026 | 8-K | Regulation FD disclosure | Document |
| Jul 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 22, 2026 | 8-K | Officer or director change | Document |
| Jul 17, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 25, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jun 3, 2026 | 8-K | Shareholder vote | Document |
| Jun 1, 2026 | 8-K | Regulation FD disclosure | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations | Document |
| Apr 22, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 29, 2016.
The full analysis
What do Keros Therapeutics's filings show?
The filings are where every one of Keros Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.